Brief: Context, Wisconsin Oncology Network Announce First Patient Dosed In Phase 2 Trial Of ONA-XR In Metastatic Breast Cancer
27/10/2021 13:27
Oct 27 (Reuters) - Context Therapeutics Inc:
* CONTEXT THERAPEUTICS® AND WISCONSIN ONCOLOGY NETWORK
ANNOUNCE
FIRST PATIENT DOSED IN PHASE 2 TRIAL OF ONA-XR IN METASTATIC
BREAST CANCER
Source text for Eikon: ID:nGNX724jxw
Further company coverage: CNTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Context Therapeutics
See all newsContext Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Context Therapeutics Q2 net loss widens on higher R&D costs
Context Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Context Therapeutics Announces Positive Interim Efficacy And Safety Results From Ongoing Phase 1 Clinical Trial For CTIM-76
Brief: Context Therapeutics Enters Into License Agreement Amendment With BioAtla For CT-202